Alnylam's TTR Amyloidosis Drug Receives Orphan Drug Designation in Europe
January 27, 2011
Alnylam's TTR Amyloidosis Drug Receives Orphan Drug Designation in Europe
Specifically, the designation is for the use of the drug against familial amyloidotic polyneuropathy, one of the predominant forms of the disease, Alnylam said.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Alnylam Receives Orphan Drug Status for Amyloidosis Drug
June 21, 2012 / Gene Silencing News - Alnylam Focuses on Two Lead Programs, Won't Advance Others without Partners
January 12, 2012 / Gene Silencing News - Unveiling New Strategy, Alnylam Aims to Debut Five Clinical Candidates by 2015
January 6, 2011 / Gene Silencing News - Alnylam to Release Phase II ATTR Data, Launch Expansion Trial in Coming Months
May 9, 2013 / Gene Silencing News - Tekmira Provides Pipeline Update, Eyes Agricultural Market
February 14, 2013 / Gene Silencing News